We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+71.33%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$910M
AUM Growth
+$326M
Cap. Flow
+$35.9M
Cap. Flow %
3.94%
Top 10 Hldgs %
64.43%
Holding
33
New
2
Increased
10
Reduced
4
Closed
4

Top Buys

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$22.8M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$19.9M
3
BPMC
Blueprint Medicines
BPMC
+$15.4M
4
SAGE
Sage Therapeutics
SAGE
+$12.7M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$7.53M

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$50.4M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$6.41M
3
IBB icon
iShares Biotechnology ETF
IBB
+$5.79M
4
NVTA
Invitae Corporation
NVTA
+$3.53M
5
GNMK
GenMark Diagnostics, Inc
GNMK
+$2.96M

Sector Composition

Rank Sector Weight
1 Healthcare 79.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDNA icon
26
CareDx
CDNA
$2.48B
$6.3M 0.69%
200,000
– –
ALEC icon
27
Alector
ALEC
$168M
$6.2M 0.68%
+331,039
New +$6.26M
GILD icon
28
Gilead Sciences
GILD
$163B
$5.2M 0.57%
+80,000
New +$5.32M
DNLI icon
29
Denali Therapeutics
DNLI
$3.67B
$2.32M 0.26%
100,000
– –
IBB icon
30
iShares Biotechnology ETF
IBB
$9.18B
– –
-60,000
Closed -$5.79M
QTNT
31
DELISTED
Quotient Limited Ordinary Shares
QTNT
– –
-8,125
Closed -$1.99M
NTGN
32
DELISTED
Neon Therapeutics, Inc. Common Stock
NTGN
– –
-263,344
Closed -$1.32M
LOXO
33
DELISTED
Loxo Oncology, Inc
LOXO
– –
-360,000
Closed -$50.4M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q1 2019 Portfolio in Review

As of Q1 2019, Casdin Capital held 33 positions worth $910M, up 56% from $585M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Casdin Capital deployed $35.9M of net new capital in Q1 2019, opening 2 new positions and adding to 10 existing holdings. Its largest new stake was Alector: 331,039 shares worth $6.2M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 86% a quarter earlier.

On the sell side, the largest reduction was Agios Pharmaceuticals, an estimated $6.41M trimmed.

  • Casdin Capital's largest Q1 2019 buy was Alector: 331,039 shares worth $6.2M.
  • Casdin Capital added most to MyoKardia, Inc. Common Stock in Q1 2019, an estimated $22.8M increase.
  • Casdin Capital's biggest Q1 2019 reduction was Agios Pharmaceuticals, cutting an estimated $6.41M.
  • Casdin Capital fully exited Loxo Oncology, Inc in Q1 2019, selling an estimated $50.4M.
  • Casdin Capital's ten largest holdings make up 64% of its $910M portfolio in Q1 2019.
  • Casdin Capital opened 2 new positions and closed 4 in Q1 2019.
  • Casdin Capital's portfolio value rose 56% quarter-over-quarter to $910M.

Based on Casdin Capital's 13F filing for Q1 2019, filed 15 May 2019.